In 2020, an article published in Science reported that complete and durable control of MM requires infusion of tumor-specific CD8+T cells with stem cell-like profiles, which were mainly CD39−CD69−CD8+ T cells that co-expressed Tcf1 (102). Here, CD8A is linked to Miyoshi myopathy.